Study finds little agreement between Republicans and Democrats on media sources they trust
Pew's survey, released Tuesday, illustrates how the country's political polarization has members of both parties in different media silos. Democrats trust more news sources than Republicans, and rarely do their tastes intersect.
Of 30 news sources tested, people who said they were Republican or leaned Republican were more likely to say they trust eight of them. Democrats had more trust than distrust for 23 different sources. Forbes and The Wall Street Journal were the only two on both lists.
There were only two news sources tested that more than three in 10 Republicans said they were likely to trust — Fox News Channel, with 56%, and the Joe Rogan podcast, with 31%.
Meanwhile, 13 of the sources had trust levels of more than 30% among Democrats — the three broadcast news divisions, PBS, CNN, BBC, The New York Times, The Associated Press, MSNBC, National Public Radio, USA Today, The Washington Post and The Wall Street Journal.
Rogan's podcast illustrated some of the sharp differences between the parties and why President Donald Trump's interview there proved influential during the last election. Forty percent of Democrats said they distrust Rogan's show as a source, while only 3% of Democrats trust it as a news source. Others said they didn't know enough about the show to offer an opinion.
Nearly two of three Democrats said they distrust Fox News, but 19% said they trust it. Among Republicans, 21% said they distrust Fox.
The survey finds that 23% of Republicans said they trust PBS, while 26% distrust PBS. Democrats trust PBS by a 59% to 4% margin.
Trump, a Republican, is trying to eliminate most government spending for PBS, arguing that its news content shows a liberal bias. Pew's survey indicates Republicans are fairly evenly divided on that question.
That's not the case for NPR, which is also on Trump's chopping block. Pew finds that more than twice as many Republicans distrust NPR than trust it, while Democrats trust NPR by a 47% to 3% margin.
'It's still a very polarized media ecosystem,' said Elisa Shearer, a senior researcher at Pew. 'It's too early to tell if there will be changes in the future.'
A separate Pew survey from March found that 53% of Republicans expressed at least some trust in the information they get from national news organizations, up from 40% only six months earlier. But Shearer said it was tough to tell how much of that increase simply had to do with a new Republican administration taking charge.
For the survey released on Tuesday, Pew said it questioned 9,482 U.S. adults in mid-March.
PBS says Trump's effort to rescind funding for public media would disrupt an essential service provided to the American people.
___
David Bauder writes about media for the AP. Follow him at http://x.com/dbauder and https://bsky.app/profile/dbauder.bsky.social.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
The Open Group Launches The Open Group Open Digital Transformation™ Forum
Standards body aims to spur faster, more effective transformation initiatives SAN FRANCISCO, July 28, 2025--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. "The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation," commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. "By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices." Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. "Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge," said Steve Nunn, President and CEO of The Open Group. "Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment." To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. View source version on Contacts Media contact Monika BoudovaHotwire for The Open GroupUKOpengroup@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio